Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tailored therapeutic approaches in acute myeloid leukaemia

Tailored therapeutic approaches in acute myeloid leukaemia PURPOSE OF REVIEW: In recent years new molecular markers have emerged as significant prognostic parameters and as potential targets for molecularly targeted therapy in acute myeloid leukaemia (AML). Prognostic markers, however, cannot guide the decision for a specific treatment since they are associated with a differential outcome regardless of the given treatment. In contrast, predictive markers indicate a treatment benefit in patients that are characterized through these markers. Thus predictive markers can guide clinical decision-making. RECENT FINDINGS: In young adults mutations of the NPM1 (NPM1 mut) gene in the absence of concurrent FLT3-ITD (FLT3-ITDneg) mutations have impressive prognostic and beyond prognostication also predictive properties. This NPM1 mut/FLT3-ITDneg genotype predicts equivalent favourable outcome after intensive chemotherapy and allogeneic stem cell transplantation, whereas in the absence of this marker clinical outcome was significantly improved after an allogeneic transplantation. In addition, within a retrospective study performed in older adults the same genotype predicted a significantly improved outcome if all-trans retinoic acid was added to intensive chemotherapy. SUMMARY: The discovery of new prognostic and predictive markers has increased our understanding of leukaemogenesis thus leading to an improved prognostication. Furthermore, current clinical research focusing on the assessment of genotype-specific therapy may translate into an increase in the cure rate. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Tailored therapeutic approaches in acute myeloid leukaemia

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/tailored-therapeutic-approaches-in-acute-myeloid-leukaemia-iA0RODm62m
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-009-0095-9
Publisher site
See Article on Publisher Site

Abstract

PURPOSE OF REVIEW: In recent years new molecular markers have emerged as significant prognostic parameters and as potential targets for molecularly targeted therapy in acute myeloid leukaemia (AML). Prognostic markers, however, cannot guide the decision for a specific treatment since they are associated with a differential outcome regardless of the given treatment. In contrast, predictive markers indicate a treatment benefit in patients that are characterized through these markers. Thus predictive markers can guide clinical decision-making. RECENT FINDINGS: In young adults mutations of the NPM1 (NPM1 mut) gene in the absence of concurrent FLT3-ITD (FLT3-ITDneg) mutations have impressive prognostic and beyond prognostication also predictive properties. This NPM1 mut/FLT3-ITDneg genotype predicts equivalent favourable outcome after intensive chemotherapy and allogeneic stem cell transplantation, whereas in the absence of this marker clinical outcome was significantly improved after an allogeneic transplantation. In addition, within a retrospective study performed in older adults the same genotype predicted a significantly improved outcome if all-trans retinoic acid was added to intensive chemotherapy. SUMMARY: The discovery of new prognostic and predictive markers has increased our understanding of leukaemogenesis thus leading to an improved prognostication. Furthermore, current clinical research focusing on the assessment of genotype-specific therapy may translate into an increase in the cure rate.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jan 1, 2009

References

  • The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties
    Grimwade, D; Walker, H; Oliver, F
  • Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    Byrd, JC; Mrózek, K; Dodge, RK
  • Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B
    Fröhling, S; Schlenk, RF; Kayser, S
  • FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
    Kelly, LM; Liu, Q; Kutok, JL
  • Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
    Schlenk, RF; Döhner, K; Krauter, J
  • Gimema Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
    Falini, B; Mecucci, C; Tiacci, E
  • Nucleophosmin and cancer
    Grisendi, S; Mecucci, C; Falini, B
  • Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)
    Thiede, C; Koch, S; Creutzig, E
  • Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
    Döhner, K; Schlenk, RF; Habdank, M
  • The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
    Kottaridis, PD; Gale, RE; Frew, ME
  • Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
    Fröhling, S; Schlenk, RF; Breitruck, J
  • Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
    Thiede, C; Steudel, C; Mohr, B
  • Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
    Yamamoto, Y; Kiyoi, H; Nakano, Y
  • Point mutations in the juxtamembrane domain of the FLT3 define a new class of activating mutations in AML
    Reindl, C; Bagrintseva, K; Vempati, S
  • Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
    Fröhling, S; Scholl, C; Levine, RL
  • FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
    Mead, AJ; Linch, DC; Hills, RK
  • FLT3 D835/I836 mutations are associated with poor disease free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplication
    Whitman, SP; Ruppert, AS; Radmacher, MD
  • Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia
    Pabst, T; Mueller, BU; Zhang, P
  • CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations
    Fröhling, S; Schlenk, RF; Stolze, I
  • The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
    Gale, RE; Green, C; Allen, C
  • Cytogenetically normal acute myeloid leukemia
    Büchner, T; Berdel, WE; Kienast, J
  • Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML
    Bornhäuser, M; Illmer, T; Schaich, M
  • No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
    Gale, RE; Hills, R; Kottaridis, PD
  • WHO classification of tumours of haematopoietic and lymphoid tissues
    Arber, DA; Vardiman, JW; Brunning, RD
  • Nucleophosmin acts as a novel AP2alpha-binding transcriptional corepressor during cell differentiation
    Liu, H; Tan, BC; Tseng, KH
  • Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
    Schlenk, RF; Fröhling, S; Hartmann, F
  • Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under Age 61
    Stone, R; Fischer, T; Paquette, R
  • Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)
    Preudhomme, C; Sagot, C; Boissel, N